

**1. NAME OF THE MEDICINAL PRODUCT**

**BRODCEF-200**

(Cefixime Tablets USP 200 mg)

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film coated Tablet contains:

Cefixime USP (as Trihydrate)

Eq. to Anhydrous Cefixime 200 mg

Colour : Titanium Dioxide BP

Excipients with known effect:

Not applicable

For a full list of excipients, see section 6.1

**3. PHARMACEUTICAL FORM**

Solid Dosage form (Tablets)

White colored, circular, biconvex film coated tablets, embossed “200” on one side and plain on other side.

**4. Clinical particulars**

**4.1 Therapeutic indications**

BRODCEF-200 is indicated for treatment of the following conditions:

- Infections of the urinary system which are not complicated due to proteus mirabilis and E. coli.
- Otitis Media caused by Streptococcus pyogenes, H. influenzae and Moraxella catarrhalis.
- Urethral or cervical gonorrhoea which is not complicated due to N. gonorrhoeae.
- Acutely developed exacerbations of Chronic Bronchitis and acutely developed Bronchitis due to H. influenzae and pneumococci.

**4.2 Posology and method of administration**

Absorption of Cefixime is not significantly modified by the presence of food. The usual course of treatment is 7 days. This may be continued for up to 14 days if required.

**Adults and Children over 10 Years:** The recommended adult dosage is 200-400 mg daily according to the severity of infection, given either as a single dose or in two divided doses.

**The Elderly:** Elderly patients may be given the same dose as recommended for adults. Renal function should be assessed and dosage should be adjusted in severe renal impairment.

**Children (Use Paediatric Oral Suspension):** The recommended dosage for children is 8 mg/kg/day administered as a single dose or in two divided doses. As a general guide for prescribing in children the following daily doses in terms of volume of Paediatric Oral Suspension are suggested:

6 months up to 1 year:	3.75 ml daily
Children 1-4 years:	5 ml daily
Children 5-10 years:	10 ml daily

Children weighing more than 50 kg or older than 10 years should be treated with the recommended adult dose (200 - 400 mg daily depending on the severity of infection).

The safety and efficacy of cefixime has not been established in children less than 6 months.

**Dosage In Renal Impairment:** BRODCEF-200 may be administered in the presence of impaired renal function. Normal dose and schedule may be given in patients with creatinine clearances of 20 ml/min or greater. In patients whose creatinine clearance is less than 20 ml/min, it is recommended that a dose of 200 mg once daily should not be exceeded. The dose and regimen for patients who are maintained on chronic ambulatory peritoneal dialysis or haemodialysis should follow the same recommendation as that for patients with creatinine clearances of less than 20 ml/min.

**Method/Mode of administration:** Oral

#### 4.3 Contraindications

Patients with known hypersensitivity to cephalosporin antibiotics or any of the other

components of the product.

#### **4.4 Special warnings and precautions for use**

##### **Severe cutaneous adverse reactions**

Severe cutaneous adverse reactions such as toxic epidermal necrolysis, Stevens-Johnson syndrome and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported in some patients on cefixime. When severe cutaneous adverse reactions occur, cefixime should be discontinued and appropriate therapy and/or measures should be taken.

BRODCEF-200 should be given with caution to patients who have shown hypersensitivity to other drugs.

##### **Hypersensitivity to penicillins**

As with other cephalosporins, cefixime should be given with caution to patients with a history of hypersensitivity to penicillin, as there is some evidence of partial cross-allergenicity between the penicillins and cephalosporins.

Patients have had severe reactions (including anaphylaxis) to both classes of drugs. If an allergic effect occurs with BRODCEF-200, the drug should be discontinued and the patient treated with appropriate agents if necessary.

##### **Haemolyticaemia**

Drug-induced haemolyticaemia, including severe cases with a fatal outcome, has been described for cephalosporins (as a class). The recurrence of haemolyticaemia after re-administration of cephalosporins in a patient with a history of cephalosporin (including cefixime) –associated haemolyticaemia has also been reported.

##### **Renal failure acute**

As with other cephalosporins, cefixime may cause acute renal failure including tubulointerstitial nephritis as an underlying pathological condition. When acute renal failure occurs, cefixime should be discontinued and appropriate therapy and/or measures should be taken.

##### **Renal impairment**

BRODCEF-200 should be administered with caution in patients with markedly impaired renal function.

#### Paediatric use

Safety of cefixime in premature or newborn infant has not been established.

Treatment with broad spectrum antibiotics alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by *Clostridium difficile* is a primary cause of antibiotic-associated diarrhoea. Pseudomembranous colitis is associated with the use of broad-spectrum antibiotics (including macrolides, semi-synthetic penicillins, lincosamides and cephalosporins); it is therefore important to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Symptoms of pseudomembranous colitis may occur during or after antibiotic treatment.

Management of pseudomembranous colitis should include sigmoidoscopy, appropriate bacteriologic studies, fluids, electrolytes and protein supplementation. If the colitis does not improve after the drug has been discontinued, or if the symptoms are severe, oral vancomycin is the drug of choice for antibiotic-associated pseudomembranous colitis produced by *C. difficile*. Other causes of colitis should be excluded.

### **4.5 Interaction with other medicinal products and other forms of interaction**

#### **Anticoagulants**

In common with other cephalosporins, increases in prothrombin times have been noted in a few patients. Care should therefore be taken in patients receiving anticoagulation therapy.

Cefixime should be administered with caution to patients receiving coumarin-type anticoagulants, e.g. warfarin potassium. Since cefixime may enhance effects of the anticoagulants, prolonged prothrombin time with or without bleeding may occur.

#### **Other forms of interaction**

A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions or with copper sulphate test tablets, but not with tests based on enzymatic glucose oxidase reactions.

A false positive direct Coombs test has been reported during treatment with cephalosporin antibiotics, therefore it should be recognised that a positive Coombs test may be due to the drug.

#### **4.6 Pregnancy and Lactation**

Reproduction studies have been performed in mice and rats at doses up to 400 times the human dose and have revealed no evidence of impaired fertility or harm to the foetus due to cefixime. In the rabbit, at doses up to 4 times the human dose, there was no evidence of a teratogenic effect; there was a high incidence of abortion and maternal death which is an expected consequence of the known sensitivity of rabbits to antibiotic-induced changes in the population of the microflora of the intestine. There are no adequate and well-controlled studies in pregnant women. BRODCEF-200 should therefore not be used in pregnancy or in nursing mothers unless considered essential by the physician.

#### **4.7 Effects on ability to drive and use machines**

Not Available

#### **4.8 Undesirable effects**

GI disturbances, Headache, Dizziness, and Rashes

#### **4.9 Overdose**

There is no experience with overdoses with BRODCEF-200.

Adverse reactions seen at dose levels up to 2 g Cefixime in normal subjects did not differ from the profile seen in patients treated at the recommended doses. Cefixime is not removed from the circulation in significant quantities by dialysis.

No specific antidote exists. General supportive measures are recommended

### **5. PHARMACOLOGICAL PROPERTIES**

#### **5.1 Pharmacodynamics properties**

Cefixime is an oral third generation cephalosporin which has marked *in vitro* bactericidal activity against a wide variety of Gram-positive and Gram-negative organisms.

Clinical efficacy has been demonstrated in infections caused by commonly occurring

pathogens including *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Escherichia coli*, *Proteus mirabilis*, *Klebsiella* species, *Haemophilus influenzae* (beta-lactamase positive and negative), *Branhamellacatarrhalis* (beta-lactamase positive and negative) and *Enterobacter* species. It is highly stable in the presence of beta-lactamase enzymes.

Most strains of enterococci (*Streptococcus faecalis*, group D Streptococci) and Staphylococci (including coagulase positive and negative strains and meticillin-resistant strains) are resistant to cefixime. In addition, most strains of *Pseudomonas*, *Bacteroides fragilis*, *Listeria monocytogenes* and Clostridia are resistant to cefixime.

## 5.2 Pharmacokinetic properties

The absolute oral bioavailability of cefixime is in the range of 22-54%. Absorption is not significantly modified by the presence of food. Cefixime may therefore be given without regard to meals.

From *in vitro* studies, serum or urine concentrations of 1 mcg/mL or greater were considered to be adequate for most common pathogens against which cefixime is active. Typically, the peak serum levels following the recommended adult or paediatric doses are between 1.5 and 3 mcg/mL. Little or no accumulation of cefixime occurs following multiple dosing.

The pharmacokinetics of cefixime in healthy elderly (age > 64 years) and young volunteers (11-35) compared the administration of 400 mg doses once daily for 5 days. Mean  $C_{max}$  and AUC values were slightly greater in the elderly. Elderly patients may be given the same dose as the general population.

Cefixime is predominantly eliminated as unchanged drug in the urine. Glomerular filtration is considered the predominant mechanism. Metabolites of cefixime have not been isolated from human serum or urine.

Serum protein binding is well characterised for human and animal sera; cefixime is almost exclusively bound to the albumin fraction, the mean free fraction being approximately 30%. Protein binding of cefixime is only concentration dependent in human serum at very high concentrations which are not seen following clinical dosing.

Transfer of <sup>14</sup>C-labelled cefixime from lactating rats to their nursing offspring through breast milk was quantitatively small (approximately 1.5% of the mothers' body content of cefixime in the pup). No data are available on secretion of cefixime in human breast milk. Placental transfer of cefixime was small in pregnant rats dosed with labelled cefixime.

### **5.3 Preclinical safety data**

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Povidone (PVP-K 30)  
Isopropyl Alcohol  
Microcrystalline Cellulose  
Colloidal Anhydrous Silica  
Magnesium Stearate  
Croscarmellose Sodium  
(Ac-Di-Sol)  
Purified Talc  
Insta Coat ICS223 White  
Dichloromethane

### **6.2 Incompatibilities**

Not applicable

### **6.3 Shelf life**

36 months

### **6.4 Special precautions for storage**

Store below 30°C protected from light.  
Keep medicines out of reach of children

### **6.5 Nature and contents of container and special equipment for use, administration or implantation**

Alu/Alu Blister pack of 10 tablets, with insert packed in carton.

**6.6 Special precautions for disposal and other handling**

No special requirements

**7. APPLICANT/MANUFACTURER  
SAM PHARMACEUTICAL LIMITED  
8/9, OYADIRAN ESTATE, SABO, YABA,  
LAGOS, NIGERIA.**

**VAPI CARE PHARMA PVT. LTD  
Plot No. 225/3, GIDC, Nr. Morarji  
Circle, Vapi - 396195. Gujarat, INDIA**

**8. MARKETING AUTHORISATION NUMBER(S)**

**A4-5062**

**9. RENEWAL OF AUTHORISATION:  
RENEWAL**

**10. DATE OF REVISION OF THE TEXT:**

**APRIL 2025**



